Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-1387 in Chronic Hepatitis B
NCT03585322Phase 1Completed
- Sponsor
- Ascentage Pharma
- Start
- Jul 2018
- Primary completion
- Oct 2021
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of dasminapant in Chronic Hepatitis B (CHB), sponsored by Ascentage Pharma. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jul 2018; status: completed.
02
Drugs
dasminapant
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03585322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03585322.